The prevalence of CH, defined as a VAF exceeding 2%, notably increased with patient age across all three groups, which was evident when age at venipuncture for the CH test (AgeCH) was categorized into two groups (younger than and older than or equal to 50 years) (Fig. 2A) or by decades (Fig. S5A). The gene discussed is C4B; the disease is cyclic hematopoiesis.